In 1966, the Chief of Urology asked the Chief of Pathology at the Minneapolis VA Hospital to develop a system to communicate the results of prostate cancer to researchers. The Chief of Pathology was Donald Gleason and he developed a system that would revolutionise our understanding of prostate cancer. Today, every prostate cancer worldwide is classified using the Gleason score, named after Donald Gleason.

Prostate cancer is one of the most common cancers worldwide and accounts for 15% of all male cancers. Its incidence of prostate cancer is estimated to double by 2040.

This is the story of prostate cancer.

Our special guests:

Professor Fiona Maclean is a Clinical Professor, Anatomical Pathologist, author, past President of the Australasian Division of the International Academy of Pathology (IAP), and advisor in Pathology Artificial Intelligence.

Dr Joanna Olphert is a urologist and robotic surgeon involved in genitourinary reconstructive surgery, robotic uro-oncology, and open complex peritoneal surgery.

Dr Carole Harris is a medical oncologist, senior lecturer, and senior research fellow.

See omnystudio.com/listener for privacy information.

Over the last 100 years, numerous types of implants (i.e. ivory, glass, wool) and injections (i.e. epoxy resin, beeswax, paraffin) have been used in an attempt for breast augmentation but the results were poor. In 1962, the first operation using silicone implants was performed and it revolutionised breast surgery. Breast augmentation surgery (cosmetic and reconstructive) is one of the most common cosmetic surgeries in Australia, United States, and the United Kingdom.

As one of the most common cosmetic surgeries, it is important for doctors and patients to know about the risks and myths of this procedure. In this episode, we discuss breast augmentation surgery and our discussion includes common complications, risks, and breast implantation illness.

This is the story of breast augmentation

Our special guest:

Our special guest is plastic surgeon Dr Andrew Campbell-Lloyd from ACL Plastic surgery in Adelaide.

See omnystudio.com/listener for privacy information.

The interplay between genetics and medications is important but complex. Pharmacogenomic testing provides doctors with information about how individual patients may respond to certain medications (ie. fast and slow metabolisers).

The RCPA recently released guidelines for doctors about requesting patient pharmacogenomic testing before prescribing some medications. These guidelines have identified 35 medications into three pharmacogenomics testing categories: recommend, consider, and no consensus. We discuss this testing with our guest today.

This is the story of pharmacogenomics.

RCPA guidelines: https://www.rcpa.edu.au/Library/Practising-Pathology/Pharmacogenomic-Indications-in-Australia

Our special guest:

Our special guest is Professor Luke Hessen who is the manager of the Genetics Department at Douglass Hanly Moir and co-Chair of the RCPA Pharmaogenetic Advisory Group.

See omnystudio.com/listener for privacy information.